Document Detail


Artificial surfactant attenuates hyperoxic lung injury in primates. II. Morphometric analysis.
MedLine Citation:
PMID:  7649918     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Diffuse lung injury from hyperoxia is accompanied by low compliance and hypoxemia with disruption of endothelial and alveolar epithelial cell layers. Because both function and content of surfactant in diffuse lung injury decrease in animals and in humans, changes in the extent of injury during continuous hyperoxia were evaluated after treatments with a protein-free surfactant in primates. Ten baboons were ventilated with 100% O2 for 96 h and five were intermittently given an aerosol of an artificial surfactant (Exosurf). Physiological and biochemical measurements of the effects of the surfactant treatment are presented in a companion paper (Y.-C. T. Huang, A. C. Sane, S. G. Simonson, T. A. Fawcett, R. E. Moon, P. J. Fracica, M. G. Menache, C. A. Piantadosi, and S. L. Young. J. Appl. Physiol. 78: 1823-1829, 1995.) After O2 exposures, lungs were fixed and processed for electron microscopy. The cellular responses to O2 included epithelial and endothelial cell injuries, interstitial edema, and inflammation. Morphometry was used to quantitate changes in lungs of animals treated with the artificial surfactant during O2 exposure and to compare them with the untreated animals. The surfactant decreased neutrophil accumulation, increased fibroblast proliferation, and decreased changes in the volume of type I epithelial cells. Surfactant-treated animals also demonstrated better preservation of endothelial cell integrity. These responses indicate ameliorating effects of the surfactant on the pulmonary response to hyperoxia, including protection against epithelial and endothelial cell destruction. Significant interstitial inflammation and fibroblast proliferation remained, however, in surfactant-treated lungs exposed to continuous hyperoxia.
Authors:
C A Piantadosi; P J Fracica; F G Duhaylongsod; Y C Huang; K E Welty-Wolf; J D Crapo; S L Young
Related Documents :
11572478 - Update on pulmonary edema: the role and regulation of endothelial barrier function.
10375378 - Differential expression of the cyclic gmp-stimulated phosphodiesterase pde2a in human v...
3015468 - Pulmonary endothelium: a dynamic interface.
19820408 - Pharmacologic therapies on the horizon for acute lung injury/acute respiratory distress...
22455908 - Ultraviolet light transmission through the human corneal stroma is reduced in the perip...
16250878 - Transendothelial migration of monocytes: the underlying molecular mechanisms and conseq...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of applied physiology (Bethesda, Md. : 1985)     Volume:  78     ISSN:  8750-7587     ISO Abbreviation:  J. Appl. Physiol.     Publication Date:  1995 May 
Date Detail:
Created Date:  1995-09-27     Completed Date:  1995-09-27     Revised Date:  2013-09-26    
Medline Journal Info:
Nlm Unique ID:  8502536     Medline TA:  J Appl Physiol (1985)     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1823-31     Citation Subset:  IM; S    
Affiliation:
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aerosols
Animals
Blood Gas Analysis
Cell Division / drug effects
Drug Combinations
Endothelium / drug effects,  pathology
Fatty Alcohols / administration & dosage,  therapeutic use*
Hemodynamics / drug effects
Lung / pathology*,  ultrastructure
Lung Diseases / drug therapy*,  pathology,  physiopathology
Male
Microscopy, Electron
Oxygen / toxicity*
Papio
Phosphorylcholine*
Polyethylene Glycols / administration & dosage,  therapeutic use*
Pulmonary Alveoli / pathology
Pulmonary Surfactants / administration & dosage,  therapeutic use*
Grant Support
ID/Acronym/Agency:
P01-HL-31992/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Aerosols; 0/Drug Combinations; 0/Fatty Alcohols; 0/Polyethylene Glycols; 0/Pulmonary Surfactants; 107-73-3/Phosphorylcholine; 7782-44-7/Oxygen; 99732-49-7/dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Artificial surfactant attenuates hyperoxic lung injury in primates. I. Physiology and biochemistry.
Next Document:  Increased prostacyclin production during exercise in untrained and trained men: effect of low-dose a...